Antibody Therapy Section, Laboratory of Molecular Biology
Dr. Mitchell Ho received his Ph.D. in Immunology from the University of Illinois at Urbana-Champaign with a National Research Service Award fellowship. He was a postdoctoral fellow with Dr. Ira Pastan at the US National Cancer Institute (NCI) generating antibody-toxin chimeric molecules (immunotoxins) directed against cancer. Dr. Ho is currently an Investigator and Head of the Antibody Therapy Section at NCI’s Laboratory of Molecular Biology. He is a recipient of the Mesothelioma Applied Research Foundation Grant Award, the Ovarian Cancer Research Fund Individual Investigator Award, a Zi-jiang Lecture Professorship from East China Normal University (Shanghai, China), and the NCI\\\\s Intramural Innovation Award for Principal Investigators. Dr. Ho has served as Chair of the NIH Antibody Interest Group, and is currently on the Editorial Boards of several peer-reviewed journals including Scientific Reports, PLoS ONE, mAbs, and antibodies.
Surface glycoproteins, Tumor antigens, Antibody engineering.